Numerous studies have found anti-CD44 antibody treatment inhibits inflammation in rodent models of arthritis(Zeidler et al., 1995), cutaneous inflammation(Camp et al., 1993), multiple sclerosis(Brocke et al., 1999), vascular leak syndrome(Rafi-Janajreh et al., 1999), and Parkinson’s disease (Wang et al., 2022). This evidence concerns the gene CD44 and arthritic joint disease.